Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

CompletedOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions

Primary IgA Nephropathy

Interventions

DRUG

TARPEYO 4 MG Delayed Release Oral Capsule

TARPEYO dispensing claim for any dose is exposure

DRUG

RAS inhibitor

RASi dispensing claim for any dose is reference

Trial Locations (1)

Ruijin hospital, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER